Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study.

Humans Consensus Quality of Life Delphi Technique Nasal Obstruction Rhinitis / diagnosis Sinusitis / diagnosis Adrenal Cortex Hormones Chronic Disease Nasal Polyps / diagnosis

Journal

Rhinology
ISSN: 0300-0729
Titre abrégé: Rhinology
Pays: Netherlands
ID NLM: 0347242

Informations de publication

Date de publication:
01 Dec 2023
Historique:
medline: 4 12 2023
pubmed: 7 10 2023
entrez: 7 10 2023
Statut: ppublish

Résumé

Chronic rhinosinusitis (CRS) disease control is a global metric of disease status for CRS. While there is broad acceptance that it is an important treatment goal, there has been inconsistency in the criteria used to define CRS control. The objective of this study was to identify and develop consensus around essential criteria for assessment of CRS disease control. Modified Delphi methodology consisting of three rounds to review a list of 24 possible CRS control criteria developed by a 12-person steering committee. The core authorship of the multidisciplinary EPOS 2020 guidelines was invited to participate. Thirty-two individuals accepted the invitation to participate and there was no dropout of participants throughout the entire study (3 rounds). Consensus essential criteria for assessment of CRS control were: overall symptom severity, need for CRS-related systemic corticosteroids in the prior 6 months, severity of nasal obstruction, and patient-reported CRS control. Near-consensus items were: nasal endoscopy findings, severity of smell loss, overall quality of life, impairment of normal activities and severity of nasal discharge. Participants’ comments provided insights into caveats of, and disagreements related to, near-consensus items. Overall symptom severity, use of CRS-related systemic corticosteroids, severity of nasal obstruction, and patient-reported CRS control are widely agreed upon essential criteria for assessment of CRS disease control. Consideration of near-consensus items to assess CRS control should be implemented with their intrinsic caveats in mind. These identified consensus CRS control criteria, together with evidence-based support, will provide a foundation upon which CRS control criteria with wide-spread acceptance can be developed.

Sections du résumé

BACKGROUND BACKGROUND
Chronic rhinosinusitis (CRS) disease control is a global metric of disease status for CRS. While there is broad acceptance that it is an important treatment goal, there has been inconsistency in the criteria used to define CRS control. The objective of this study was to identify and develop consensus around essential criteria for assessment of CRS disease control.
METHODS METHODS
Modified Delphi methodology consisting of three rounds to review a list of 24 possible CRS control criteria developed by a 12-person steering committee. The core authorship of the multidisciplinary EPOS 2020 guidelines was invited to participate.
RESULTS RESULTS
Thirty-two individuals accepted the invitation to participate and there was no dropout of participants throughout the entire study (3 rounds). Consensus essential criteria for assessment of CRS control were: overall symptom severity, need for CRS-related systemic corticosteroids in the prior 6 months, severity of nasal obstruction, and patient-reported CRS control. Near-consensus items were: nasal endoscopy findings, severity of smell loss, overall quality of life, impairment of normal activities and severity of nasal discharge. Participants’ comments provided insights into caveats of, and disagreements related to, near-consensus items.
CONCLUSIONS CONCLUSIONS
Overall symptom severity, use of CRS-related systemic corticosteroids, severity of nasal obstruction, and patient-reported CRS control are widely agreed upon essential criteria for assessment of CRS disease control. Consideration of near-consensus items to assess CRS control should be implemented with their intrinsic caveats in mind. These identified consensus CRS control criteria, together with evidence-based support, will provide a foundation upon which CRS control criteria with wide-spread acceptance can be developed.

Identifiants

DOI: 10.4193/Rhin23.335 PMID: 37804121
pubmed: 37804121
pii: 3118
doi: 10.4193/Rhin23.335
doi:

Substances chimiques

Adrenal Cortex Hormones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

519-530

Auteurs

A R Sedaghat (AR)

Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

W J Fokkens (WJ)

Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.

V J Lund (VJ)

Royal National ENT Hospital, University College London Hospital NHS Foundation Trust, London, UK.

P W Hellings (PW)

Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, KU Leuven, Belgium.

R C Kern (RC)

Department of Otorhinolaryngology, Head and Neck Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.

S Reitsma (S)

Department of Otorhinolaryngology and Head and Neck Surgery, Amsterdam University Medical Centres, location AMC, Amsterdam, The Netherlands.

S Toppila-Salmi (S)

Department of Otorhinolaryngology, Kuopio University Hospital and University of Eastern Finland, Finland and Department of Allergy, Inflammation Center, Helsinki University Hospital and University of Helsinki, Finland.

M Bernal-Sprekelsen (M)

Department of ORL, Hospital Clinic, University of Barcelona, Spain.

J Mullol (J)

Rhinology Unit and Smell Clinic, ENT Department, Hospital Clinic, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.

P Gevaert (P)

Department of Otorhinolaryngology, Ghent University, Ghent, Belgium.

T Teeling (T)

Patient representative, Task Force Healthcare, WTC Den Haag, The Netherlands.

I Alobid (I)

Rhinology and Skull Base Unit, ENT Department, Hospital Clinic, Universitat de Barcelona, August Pi i Sunyer Biomedical Research Institute, CIBERES, Barcelona, Spain.

W T Anselmo-Lima (WT)

Division of Otorhinolaryngology, Department of Ophthalmology, Otorhinolaryngology, Head and Neck Surgery, Ribeirao Preto Medical School-University of Sao Paulo, Sao Paulo, Brazil.

F M Baroody (FM)

Department of Otorhinolaryngology-Head and Neck Surgery, The University of Chicago Medicine and the Comer Children’s Hospital, Chicago, IL, USA.

A Cervin (A)

Department of Otorhinolaryngology, Head and Neck Surgery, Royal Brisbane and Women's Hospital; Faculty of Medicine, University of Queensland, Brisbane, Australia and Department of Clinical Sciences, Lund University, Lund, Sweden.

N A Cohen (NA)

Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA, USA.

J Constantinidis (J)

1st Department of ORL, Head and Neck Surgery, Aristotle University, AHEPA Hospital, Thessaloniki, Greece.

L De Gabory (L)

Rhinology and Plastic Surgery Unit, Otorhinolaryngology, Head and Neck Surgery and Pediatric ENT Department, CHU ux, Hospital Pellegrin, Centre F-X Michelet, Bordeaux, France.

M Desrosiers (M)

Department of ORL-HNS, Universitat de Montreal, Montreal, Canada.

R J Harvey (RJ)

Rhinology and Skull Base Department, Applied Medical Research Centre, UNSW (Conjoint) and Macquarie University (Clinical), Sydney, Australia.

L Kalogjera (L)

Department of Otorhinolaryngology/Head and Neck Surgery, Zagreb School of Medicine; University Hospital Center, Sestre milosrdnice,Zagreb, Croatia.

A Knill (A)

Patient representative, Sinus UK, London, UK.

B N Landis (BN)

Rhinology-Olfactology Unit, Otorhinolaryngology Department, University Hospital of Geneva, Geneva, Switzerland.

C Meco (C)

Department of Otorhinolaryngology, Head and Neck Surgery, Ankara University, Ankara, Turkey and Department of Otorhinolaryngology, Head and Neck Surgery, Salzburg Paracelsus Medical University, Salzburg, Austria.

C M Philpott (CM)

Rhinology and ENT Research Group, Norwich Medical School, University of East Anglia, Norwich, UK and Norfolk and Waveney ENT Service, James Paget University Hospital, Great Yarmouth and Norfolk and Norwich University Hospital, Norwich, UK.

D Ryan (D)

Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, Scotland, UK and International Primary Care Respiratory Group, Edinburgh, Scotland, UK.

R J Schlosser (RJ)

Department of Otolaryngology - Head and Neck Surgery, Medical University of South Carolina, Charleston, SC, USA.

B A Senior (BA)

Department of Otolaryngology - Head and Neck Surgery, University of North Carolina, Chapel Hill, NC, USA.

T L Smith (TL)

Division of Rhinology and Sinus Surgery, Oregon Sinus Center, Oregon Health.

P V Tomazic (PV)

Department of Otorhinolaryngology, Medical University of Graz, Graz, Austria.

L Zhang (L)

Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China and Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing, China and Beijing Institute of Otolaryngology, Beijing Laboratory of Allergic Diseases, Beijing Key Laboratory of Nasal Diseases, Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education, Capital Medical University, Beijing, China and Research Unit of Diagnosis and T.

C Hopkins (C)

Department of Otolaryngology and Head Neck Surgery, Guys and St Thomas’ Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › Sciences de l'information › Analyse des systèmes › Méthode Delphi › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › Maladies oto-rhino-laryngologiques › Maladies du nez › Obstruction nasale › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › Maladies oto-rhino-laryngologiques › Maladies du nez › Rhinite › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › Maladies oto-rhino-laryngologiques › Maladies du nez › Maladies des sinus › Sinusite › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › Hormones corticosurrénaliennes › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Consensus criteria for chronic rhinosinusitis...
questionsmedicales.fr › États, signes et symptômes pathologiques › États anatomopathologiques › Polypes › Polypes du nez › Consensus criteria for chronic rhinosinusitis...